By Natan Ponieman and Javier Hasse
The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other serious conditions.
Running an early-stage biotechnology company while navigating the terrain of regulatory approvals is a tough business. Here’s a list of the psychedelic medicine industry’s top CEOs.
Psychedelic Industry CEOs
- Rob Barrow: MindMed
- Florian Brand: Atai Life Sciences
- Doug Drysdale: Cybin
- Joseph del Moral: Field Trip Health
- George Goldsmith: Compass Pathways
- Payton Nyquvest: Numinus
- Dr. Joseph Tucker: MagicMed
- Dr. Roger McIntyre: Braxia Health
- Kelsey Ramsden: MindCure
- Yaron Conforti: Novamind
- Daniel Carcillo: Wesana Health
- Raj Mehra: Seelos Therapeutics
Rob Barrow: MindMed
Mind Medicine Inc. (NASDAQ: MNMD), also known as MindMed, is an industry leader. One of the first psychedelic medicine companies to go public, MindMed has a diverse development pipeline, impressive team and a loyal base of passionate investors. From LSD, to MDMA, to DMT, MindMed is working to treat everything from opioid addiction to headaches to ADHD.
Rob Barrow is MindMed’s new CEO. A pharmaceutical executive and pharmacologist, Barrow has a wealth of experience leading drug development teams and navigating the pharmaceutical approval landscape. Barrow previously served as Director at the Usona Institute, where he managed the clinical and regulatory efforts focused on psychedelics. Taking over from founder and former CEO JR Rahn, Barrow seems a good fit to lead MindMed into its next stage of development.
Florian Brand: Atai Life Sciences
Atai (NASDAQ: ATAI) is currently the psychedelic medicine industry’s largest company (by market value). Debuting on the Nasdaq exchange earlier this year, the company owns and/or operates over 10 different companies developing a range of psychedelic and non-psychedelic medicines. Atai is the most well-funded company in the industry and is backed by s big-name investors like PayPal (NASDAQ: PYPL) co-founder Peter Thiel.
Florian Brand, co-founder and CEO of Atai Life Sciences, is a successful entrepreneur who is passionate about finding ways to solve mental health disorders. Co-founder and chairman Christian Angermayer is also a major part of the executive leadership team.
Doug Drysdale: Cybin
Cybin (NYSE: CYBN) is a Toronto-based psychedelic medicine firm. Having gone public on the NEO exchange in November 2020, the firm has been steadily growing its market cap and development pipeline. The company recently became the industry’s first to list on the NYSE American exchange.
CEO Doug Drysdale is an experienced director, having been CEO and chairman of the board of NASDAQ-listed companies and other pharmaceutical firms. Drysdale has spent nearly 30 years in the healthcare sector, helping turn around a variety of companies and take them to the next level.
Joseph del Moral: Field Trip Health
Field Trip Health (NASDAQ: FTRP) is the current industry leader of in-person treatment clinics. With locations across North America and Europe and with plans to open seventy-five clinics by the end of 2024, Field Trip has a first-mover advantage in the all-important area of actually delivering therapies to people in need. The company is …